Headlines about EnteroMedics (NASDAQ:RSLS) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. EnteroMedics earned a news impact score of 0.05 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 47.7990778206865 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
EnteroMedics (NASDAQ:RSLS) opened at $1.59 on Tuesday. EnteroMedics has a one year low of $1.47 and a one year high of $30.41.
EnteroMedics (NASDAQ:RSLS) last released its earnings results on Tuesday, November 14th. The medical device company reported ($1.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.77). The company had revenue of $0.36 million for the quarter. EnteroMedics had a negative net margin of 4,509.61% and a negative return on equity of 104.23%. equities analysts forecast that EnteroMedics will post -1.4 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.themarketsdaily.com/2017/11/21/enteromedics-rsls-given-media-impact-score-of-0-05.html.
EnteroMedics Company Profile
ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.